Prelude Therapeutics (PRLD) Competitors $0.96 0.00 (0.00%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends PRLD vs. SLN, INBX, ZURA, EDIT, SLDB, XBIT, CRBP, AMRN, ENTA, and ADCTShould you be buying Prelude Therapeutics stock or one of its competitors? The main competitors of Prelude Therapeutics include Silence Therapeutics (SLN), Inhibrx (INBX), Zura Bio (ZURA), Editas Medicine (EDIT), Solid Biosciences (SLDB), XBiotech (XBIT), Corbus Pharmaceuticals (CRBP), Amarin (AMRN), Enanta Pharmaceuticals (ENTA), and ADC Therapeutics (ADCT). These companies are all part of the "pharmaceutical products" industry. Prelude Therapeutics vs. Silence Therapeutics Inhibrx Zura Bio Editas Medicine Solid Biosciences XBiotech Corbus Pharmaceuticals Amarin Enanta Pharmaceuticals ADC Therapeutics Prelude Therapeutics (NASDAQ:PRLD) and Silence Therapeutics (NASDAQ:SLN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, community ranking, risk, earnings, media sentiment, institutional ownership and dividends. Does the media favor PRLD or SLN? In the previous week, Silence Therapeutics had 13 more articles in the media than Prelude Therapeutics. MarketBeat recorded 14 mentions for Silence Therapeutics and 1 mentions for Prelude Therapeutics. Prelude Therapeutics' average media sentiment score of 1.95 beat Silence Therapeutics' score of 0.18 indicating that Prelude Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prelude Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Silence Therapeutics 1 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk & volatility, PRLD or SLN? Prelude Therapeutics has a beta of 1.56, meaning that its share price is 56% more volatile than the S&P 500. Comparatively, Silence Therapeutics has a beta of 1.3, meaning that its share price is 30% more volatile than the S&P 500. Which has higher valuation and earnings, PRLD or SLN? Silence Therapeutics has higher revenue and earnings than Prelude Therapeutics. Silence Therapeutics is trading at a lower price-to-earnings ratio than Prelude Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPrelude TherapeuticsN/AN/A-$121.83M-$1.78-0.54Silence Therapeutics$31.55M6.57-$53.82M-$1.57-4.41 Do institutionals and insiders believe in PRLD or SLN? 79.7% of Prelude Therapeutics shares are owned by institutional investors. Comparatively, 98.7% of Silence Therapeutics shares are owned by institutional investors. 62.8% of Prelude Therapeutics shares are owned by company insiders. Comparatively, 3.0% of Silence Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the MarketBeat Community prefer PRLD or SLN? Silence Therapeutics received 7 more outperform votes than Prelude Therapeutics when rated by MarketBeat users. Likewise, 80.00% of users gave Silence Therapeutics an outperform vote while only 48.33% of users gave Prelude Therapeutics an outperform vote. CompanyUnderperformOutperformPrelude TherapeuticsOutperform Votes2948.33% Underperform Votes3151.67% Silence TherapeuticsOutperform Votes3680.00% Underperform Votes920.00% Do analysts prefer PRLD or SLN? Prelude Therapeutics currently has a consensus target price of $4.75, suggesting a potential upside of 393.92%. Silence Therapeutics has a consensus target price of $57.20, suggesting a potential upside of 725.40%. Given Silence Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Silence Therapeutics is more favorable than Prelude Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Prelude Therapeutics 2 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.00Silence Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is PRLD or SLN more profitable? Prelude Therapeutics has a net margin of 0.00% compared to Silence Therapeutics' net margin of -342.00%. Silence Therapeutics' return on equity of -62.81% beat Prelude Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Prelude TherapeuticsN/A -66.89% -55.59% Silence Therapeutics -342.00%-62.81%-33.89% SummarySilence Therapeutics beats Prelude Therapeutics on 12 of the 17 factors compared between the two stocks. Ad Darwin2025 AI Stock Picks: 2 Hidden Gems Under $10/ShareThe AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.👉[Click here to get your FREE report delivered instantly!] Get Prelude Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRLD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRLD vs. The Competition Export to ExcelMetricPrelude TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$52.84M$6.48B$5.07B$8.89BDividend YieldN/A8.11%4.99%4.07%P/E Ratio-0.544.4283.5712.93Price / SalesN/A375.031,220.3088.33Price / CashN/A52.5939.4636.25Price / Book0.3410.126.936.25Net Income-$121.83M$153.61M$119.12M$225.93M7 Day Performance-6.63%-2.00%-1.83%-1.32%1 Month Performance-45.97%-7.47%-3.64%0.60%1 Year Performance-70.23%31.80%31.64%26.23% Prelude Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRLDPrelude Therapeutics2.9919 of 5 stars$0.96flat$4.75+393.9%-72.0%$52.84MN/A-0.54120Positive NewsSLNSilence Therapeutics3.646 of 5 stars$6.93-0.6%$57.20+725.4%-27.1%$208.60M$31.55M0.00100Analyst ForecastNews CoverageHigh Trading VolumeINBXInhibrx1.2884 of 5 stars$14.04-1.7%N/A-36.9%$206.86M$1.63M0.00166ZURAZura Bio3.9055 of 5 stars$2.90-7.9%$15.80+444.8%-35.1%$205.68MN/A0.003Analyst ForecastEDITEditas Medicine4.7809 of 5 stars$2.41-2.8%$9.08+276.9%-77.8%$204.72M$78.12M-0.94230Short Interest ↓SLDBSolid Biosciences3.3235 of 5 stars$4.96-2.9%$15.14+205.3%+108.4%$204.17M$8.09M-1.63100XBITXBiotech0.8946 of 5 stars$6.49-2.7%N/A+77.8%$203.32M$4.01M0.00100Positive NewsCRBPCorbus Pharmaceuticals4.8781 of 5 stars$16.08-2.9%$65.86+309.6%+249.6%$201.69M$880,000.00-3.4340Positive NewsAMRNAmarin0.1111 of 5 stars$0.49flatN/A-37.4%$201.52M$306.91M0.00360Negative NewsENTAEnanta Pharmaceuticals2.9547 of 5 stars$9.08-3.6%$20.00+120.3%+1.6%$199.60M$79.20M-1.67145ADCTADC Therapeutics2.8805 of 5 stars$1.98-3.9%$8.25+317.7%+177.9%$199.18M$69.56M0.00310Positive News Related Companies and Tools Related Companies Silence Therapeutics Alternatives Inhibrx Alternatives Zura Bio Alternatives Editas Medicine Alternatives Solid Biosciences Alternatives XBiotech Alternatives Corbus Pharmaceuticals Alternatives Amarin Alternatives Enanta Pharmaceuticals Alternatives ADC Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PRLD) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prelude Therapeutics Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Prelude Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PRLD Stock Alerts